Immunological Response after WT1 mRNA-loaded Dendritic Cell Immunotherapy in Ovarian Carcinoma and Carcinosarcoma

An Coosemans; Anke Vanderstraeten; Sandra Tuyaerts; Tina Verschuere; Philippe Moerman; Zwi Berneman; Ignace Vergote; Frédéric Amant; Stefaan W. van Gool

Immunological Response after WT1 mRNA-loaded Dendritic Cell Immunotherapy in Ovarian Carcinoma and Carcinosarcoma

An Coosemans, Anke Vanderstraeten, Sandra Tuyaerts, Tina Verschuere, Philippe Moerman, Zwi Berneman, Ignace Vergote, Frédéric Amant, Stefaan W. van Gool

Other Departments

Research output: Contribution to journal › Article › Academic › peer-review

42 Citations (Scopus)

Abstract

Background: Dendritic cell (DC)-based immunotherapy is an emerging new treatment option in ovarian cancer, an important cause of cancer-related mortality. Patients and Methods: One patient with ovarian carcinosarcoma (OCS) and one with serous ovarian cancer (SOC) received four weekly vaccinations of autologous DCs electroporated with mRNA coding for the Wilms' tumor gene 1 (WT1). Safety, feasibility and immunogenicity were assessed. Results: Vaccination was feasible without toxicity. In an ex vivo antigen re-stimulation assay of peripheral blood mononuclear cells, both patients showed increasing cluster of differentiation 137 (CD137+) antigen-specific T-cells and interleukin 10 (IL-10) production post-vaccination. Moreover, interleukin-2 (IL-2) production increased (OCS) as well as interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) (SOC). Disease in patients progressed after four vaccines and patients continued with conventional therapies. After cessation of immunotherapy, they had an extended survival of 19 (OCS) and 12 (SOC) months. Conclusion: To our knowledge, we report for the first time the feasibility and T-cell immunogenicity of WT1 mRNA-loaded DC immunotherapy in ovarian cancer

Original language	English
Pages (from-to)	3855-3859
Journal	Anticancer research
Volume	33
Issue number	9
Publication status	Published - 2013

Cite this

@article{3bcbcf33f8594868b2881bff1fd04a44,

title = "Immunological Response after WT1 mRNA-loaded Dendritic Cell Immunotherapy in Ovarian Carcinoma and Carcinosarcoma",

abstract = "Background: Dendritic cell (DC)-based immunotherapy is an emerging new treatment option in ovarian cancer, an important cause of cancer-related mortality. Patients and Methods: One patient with ovarian carcinosarcoma (OCS) and one with serous ovarian cancer (SOC) received four weekly vaccinations of autologous DCs electroporated with mRNA coding for the Wilms' tumor gene 1 (WT1). Safety, feasibility and immunogenicity were assessed. Results: Vaccination was feasible without toxicity. In an ex vivo antigen re-stimulation assay of peripheral blood mononuclear cells, both patients showed increasing cluster of differentiation 137 (CD137+) antigen-specific T-cells and interleukin 10 (IL-10) production post-vaccination. Moreover, interleukin-2 (IL-2) production increased (OCS) as well as interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) (SOC). Disease in patients progressed after four vaccines and patients continued with conventional therapies. After cessation of immunotherapy, they had an extended survival of 19 (OCS) and 12 (SOC) months. Conclusion: To our knowledge, we report for the first time the feasibility and T-cell immunogenicity of WT1 mRNA-loaded DC immunotherapy in ovarian cancer",

author = "An Coosemans and Anke Vanderstraeten and Sandra Tuyaerts and Tina Verschuere and Philippe Moerman and Zwi Berneman and Ignace Vergote and Fr{\'e}d{\'e}ric Amant and {van Gool}, {Stefaan W.}",

year = "2013",

language = "English",

volume = "33",

pages = "3855--3859",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "9",

}

TY - JOUR

T1 - Immunological Response after WT1 mRNA-loaded Dendritic Cell Immunotherapy in Ovarian Carcinoma and Carcinosarcoma

AU - Coosemans, An

AU - Vanderstraeten, Anke

AU - Tuyaerts, Sandra

AU - Verschuere, Tina

AU - Moerman, Philippe

AU - Berneman, Zwi

AU - Vergote, Ignace

AU - Amant, Frédéric

AU - van Gool, Stefaan W.

PY - 2013

Y1 - 2013

N2 - Background: Dendritic cell (DC)-based immunotherapy is an emerging new treatment option in ovarian cancer, an important cause of cancer-related mortality. Patients and Methods: One patient with ovarian carcinosarcoma (OCS) and one with serous ovarian cancer (SOC) received four weekly vaccinations of autologous DCs electroporated with mRNA coding for the Wilms' tumor gene 1 (WT1). Safety, feasibility and immunogenicity were assessed. Results: Vaccination was feasible without toxicity. In an ex vivo antigen re-stimulation assay of peripheral blood mononuclear cells, both patients showed increasing cluster of differentiation 137 (CD137+) antigen-specific T-cells and interleukin 10 (IL-10) production post-vaccination. Moreover, interleukin-2 (IL-2) production increased (OCS) as well as interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) (SOC). Disease in patients progressed after four vaccines and patients continued with conventional therapies. After cessation of immunotherapy, they had an extended survival of 19 (OCS) and 12 (SOC) months. Conclusion: To our knowledge, we report for the first time the feasibility and T-cell immunogenicity of WT1 mRNA-loaded DC immunotherapy in ovarian cancer

AB - Background: Dendritic cell (DC)-based immunotherapy is an emerging new treatment option in ovarian cancer, an important cause of cancer-related mortality. Patients and Methods: One patient with ovarian carcinosarcoma (OCS) and one with serous ovarian cancer (SOC) received four weekly vaccinations of autologous DCs electroporated with mRNA coding for the Wilms' tumor gene 1 (WT1). Safety, feasibility and immunogenicity were assessed. Results: Vaccination was feasible without toxicity. In an ex vivo antigen re-stimulation assay of peripheral blood mononuclear cells, both patients showed increasing cluster of differentiation 137 (CD137+) antigen-specific T-cells and interleukin 10 (IL-10) production post-vaccination. Moreover, interleukin-2 (IL-2) production increased (OCS) as well as interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) (SOC). Disease in patients progressed after four vaccines and patients continued with conventional therapies. After cessation of immunotherapy, they had an extended survival of 19 (OCS) and 12 (SOC) months. Conclusion: To our knowledge, we report for the first time the feasibility and T-cell immunogenicity of WT1 mRNA-loaded DC immunotherapy in ovarian cancer

M3 - Article

C2 - 24023319

SN - 0250-7005

VL - 33

SP - 3855

EP - 3859

JO - Anticancer research

JF - Anticancer research

IS - 9

ER -